MIASTENIYA KASALLIGINI RIVOJLANSHIDA YALLIG’LANISH MEDIATORLARINI PATOGENETIK AHAMIYATI
Article Sidebar
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Main Article Content
Аннотация:
Miasteniya Gravis – post-sinaptik neyromuskulyar birikmadagi asetil xolin retseptorlariga (AChR) yoki u bilan bog‘liq oqsillarga (MuSK, LRP4 va boshqalar) qarshi antitelolarni paydo bo’lishi bilan bog’liq bo’lgan autoimmun nafas yo’llari va tana muskullari holsizlanishi bilan kechuvchi kasallik sanaladi. Yallig‘lanish va immunologik mexanizmlar MG patogenezida muhim o‘rin egallaydi; bu maqola aynan yallig‘lanish hujayraviy jarayonlari, sitokin va plazma mediatorlari jihatidan tahlil qiladi. Ma’lumki, miasteniya kasalligi rivojlanishi to’liq autoimmun kasallik emas va balki patogenezida turli xildagi sitokilarni ishtirok etishi kasallik asosida yallig’lanish jarayoni yotganligini ko’rsatdi. Sitokinlarni qonda aniqlash va M1/M2 larni o’zaro nisbati kasalliklarni o’girlik darajasini diagnostika qilish, turlarini aniqlash va kelajakda zamonaviy davolash usullarini kelib chiqishiga olib keladi.
Article Details
Как цитировать:
Библиографические ссылки:
Абдуллаева, М. Б., Иноятова, С. О., Комилжон, М. Т., & Музаффар, М. А. (2025). МАКРОФАГИ КАК КЛЮЧЕВЫЕ МЕДИАТОРЫ В ПАТОГЕНЕЗЕ МИАСТЕНИИ. Вестник Ассоциации Пульмонологов Центральной Азии, 13(8), 114-117.
Fecto F. Myasthenia gravis: Mechanisms, clinical syndromes, and diagnosis. Dis Mon. 2025 Aug;71(8):101969.
Huang X, Li H, Zhang Z, Wang Z, Du X, Zhang Y. Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse. Cytokine. 2024 Mar;175:156485.
Huang X, An X, Gao X, Wang N, Liu J, Zhang Y, Qi G, Zhang C. Serum amyloid A facilitates expansion of CD4 T cell and CD19 B cell subsets implicated in the severity of myasthenia gravis patients. J Neurochem. 2024 Mar;168(3):224-237.
Mané-Damas M, Schöttler AK, Marcuse F, Molenaar PC, Mohile T, de Baets MH, Losen M, Martinez-Martinez P. Myasthenia gravis with antibodies against the AChR, current knowledge on pathophysiology and an update on treatment strategies with special focus on targeting plasma cells. Autoimmun Rev. 2025 Sep 24;24(10):103875.
Terroba-Navajas P, Lu IN, Quast I, Heming M, Keller CW, Ostendorf L, Hauser AE, Mothes R, Radbruch H, Stascheit F, Meisel AGO, Wiendl H, Meyer Zu Hörste G, Willcox N, Lünemann JD. Single-Cell Transcriptomics Identifies a Prominent Role for the MIF-CD74 Axis in Myasthenia Gravis Thymus. Neurol Neuroimmunol Neuroinflamm. 2025 May;12(3):
Huang X, Zhang Z, Wang Z, Luo T, Yang M, Guo X, Du X, Ma T, Zhang Y. Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis. J Neuroinflammation. 2025 Jan 24;22(1):17.
Jia K, Shao Y, Tan T, Liu X, Zhang Q, Zhao N, Yang L. Serum interleukin-40 increases in anti-AchR antibody-positive myasthenia gravis and correlates with disease activity. Front Neurol. 2025 Sep 17;16:1680530.
El-Wahsh S, Ramanathan S, Reddel S. Clinical utility of autoantibodies in the diagnosis and management of Myasthenia gravis. J Neuroimmunol. 2025 Oct 15;407:578718.
Zheng YL, Su GZ, Li YL, Du T, Zhao XL, Wang CC, Liu Y, Liu B, Duan RS, Li XL. Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review. Front Immunol. 2025 Apr 28;16:1545579
Matthews I, Sims G, Ledwidge S, et al. . Antibodies to acetylcholine receptor in parous women with myasthenia: evidence for immunization by fetal antigen. Lab Invest. 2002;82(10):1407-1417.
Huda R. Inflammation and autoimmune myasthenia gravis. Front Immunol. 2023 Jan 30;14:1110499. doi: 10.3389/fimmu.2023.1110499.